PURPOSE: To study GP-170 in superficial bladder cancer at initial diagnosis and at recurrence and to evaluate if intravesical chemoprophylaxis modifies the expression of GP-170 in tumor recurrences. MATERIALS AND METHODS: GP-170 was retrospectively assessed in 160 patients affected by primary superficial transitional cell carcinoma of the bladder and followed for up to 10 years. Eighty-four patients (52.5%) recurred after transurethral resection (TUR). Adjuvant intravesical chemotherapy after TUR was adopted in 52 patients. The correlations between GP-170 and G-grade, T-category, risk of recurrence and of progression, and adoption of adjuvant intravesical chemotherapy were investigated. The correlations between variations in grade and stage at recurrence and modifications in GP-170 expression were also studied. RESULTS: No significant correlation between GP-170 expression and G-grade and T-category was found. A significant correlation was detected between GP-170 expression and recurrence ( P=0.0383). It showed a biphasic pattern, i.e., tumors that did not express GP-170 had a higher recurrence rate, but high GP-170 levels were also associated with an increasing risk of recurrence. Intravesical chemotherapy did not induce significative variations in GP-170 expression. No correlation was found between progression and GP-170. CONCLUSION: GP-170 seems to be an independent prognostic factor for recurrence in superficial bladder tumors. A negative GP-170 pattern and high levels of GP-170 are associated with an increasing risk of recurrence but have no impact upon progression. In our experience, GP-170 is neither induced nor modified by intravesical chemotherapy, although it might represent a factor of chemoresistance when strongly expressed.
PURPOSE: To study GP-170 in superficial bladder cancer at initial diagnosis and at recurrence and to evaluate if intravesical chemoprophylaxis modifies the expression of GP-170 in tumor recurrences. MATERIALS AND METHODS:GP-170 was retrospectively assessed in 160 patients affected by primary superficial transitional cell carcinoma of the bladder and followed for up to 10 years. Eighty-four patients (52.5%) recurred after transurethral resection (TUR). Adjuvant intravesical chemotherapy after TUR was adopted in 52 patients. The correlations between GP-170 and G-grade, T-category, risk of recurrence and of progression, and adoption of adjuvant intravesical chemotherapy were investigated. The correlations between variations in grade and stage at recurrence and modifications in GP-170 expression were also studied. RESULTS: No significant correlation between GP-170 expression and G-grade and T-category was found. A significant correlation was detected between GP-170 expression and recurrence ( P=0.0383). It showed a biphasic pattern, i.e., tumors that did not express GP-170 had a higher recurrence rate, but high GP-170 levels were also associated with an increasing risk of recurrence. Intravesical chemotherapy did not induce significative variations in GP-170 expression. No correlation was found between progression and GP-170. CONCLUSION:GP-170 seems to be an independent prognostic factor for recurrence in superficial bladder tumors. A negative GP-170 pattern and high levels of GP-170 are associated with an increasing risk of recurrence but have no impact upon progression. In our experience, GP-170 is neither induced nor modified by intravesical chemotherapy, although it might represent a factor of chemoresistance when strongly expressed.
Authors: Y Tada; M Wada; K Kuroiwa; N Kinugawa; T Harada; J Nagayama; M Nakagawa; S Naito; M Kuwano Journal: Clin Cancer Res Date: 2000-12 Impact factor: 12.531
Authors: H Kubo; T Sumizawa; K Koga; K Nishiyama; Y Takebayashi; Y Chuman; T Furukawa; S Akiyama; Y Ohi Journal: Int J Cancer Date: 1996-12-20 Impact factor: 7.396
Authors: K Nooter; A M Westerman; M J Flens; G J Zaman; R J Scheper; K E van Wingerden; H Burger; R Oostrum; T Boersma; P Sonneveld Journal: Clin Cancer Res Date: 1995-11 Impact factor: 12.531
Authors: Yule Chen; Guodong Zhu; Kaijie Wu; Yang Gao; Jin Zeng; Qi Shi; Peng Guo; Xinyang Wang; Luke S Chang; Lei Li; Dalin He Journal: Tumour Biol Date: 2015-10-22
Authors: Roman A Blaheta; Frederick H Daher; Martin Michaelis; Christoph Hasenberg; Eva M Weich; Dietger Jonas; Rouslan Kotchetkov; Hans Willhelm Doerr; Jindrich Cinatl Journal: BMC Cancer Date: 2006-12-21 Impact factor: 4.430
Authors: Stefan Vallo; Martin Michaelis; Florian Rothweiler; Georg Bartsch; Kilian M Gust; Dominik M Limbart; Franz Rödel; Felix Wezel; Axel Haferkamp; Jindrich Cinatl Journal: Transl Oncol Date: 2015-06 Impact factor: 4.243